{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:05:52Z","timestamp":1787169952007,"version":"build-2736575974"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The burden of adverse cardiorenal outcomes among patients with the trifecta of diabetes, heart failure (HF) and chronic kidney disease (CKD) remains high. Steroidal mineralocorticoid receptor antagonists (MRAs) have been shown to improve clinical outcomes in patients with HF, however, there is significant underutilization of these agents, especially in patients with advanced CKD. Non-steroidal MRAs are an emerging therapeutic option for patients with diabetic kidney disease and are now guideline-supported in this population. Non-steroidal MRAs have a unique pharmacological profile distinct from their steroidal counterparts that retains the class-specific cardiorenal benefits but may help mitigate adverse effects, especially hyperkalaemia, in patients with CKD. In this review we summarize the current evidence on the use of non-steroidal MRAs for improving cardiorenal outcomes in patients with CKD and diabetes, as well as for combination use alongside other foundational medical therapies used in HF and CKD.<\/jats:p>","DOI":"10.1093\/ndt\/gfac322","type":"journal-article","created":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T08:57:15Z","timestamp":1670057835000},"page":"845-854","source":"Crossref","is-referenced-by-count":9,"title":["Non-steroidal mineralocorticoid receptor antagonists and cardiorenal outcomes in chronic kidney disease"],"prefix":"10.1093","volume":"38","author":[{"given":"Kevin Bryan","family":"Lo","sequence":"first","affiliation":[{"name":"Department of Medicine, Einstein Medical Center, Sidney Kimmel Medical College at Thomas Jefferson University , Philadelphia, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janani","family":"Rangaswami","sequence":"additional","affiliation":[{"name":"Department of Nephrology, George Washington University School of Medicine and Health Sciences , Washington DC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-1953","authenticated-orcid":false,"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women's Hospital , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/jamacardio.2016.1878","article-title":"Mineralocorticoid receptor antagonists in the management of heart failure and resistant hypertension: a review","volume":"1","author":"Flatt","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1097\/HJH.0000000000002187","article-title":"Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Alexandrou","year":"2019","journal-title":"J Hypertens"},{"key":"2023033113281082900_","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"EVIDctcs2100007","DOI":"10.1056\/EVIDctcs2100007","article-title":"Behind the scenes of TOPCAT\u2014bending to inform","volume":"1","author":"Pfeffer","year":"2022","journal-title":"NEJM Evid"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2021.05.002","article-title":"Kidney function and outcomes in patients hospitalized with heart failure","volume":"78","author":"Patel","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension"},{"key":"2023033113281082900_","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","author":"Kintscher","year":"2021","journal-title":"Br J Pharmacol"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/13543784.2021.2002844","article-title":"Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics","volume":"30","author":"Barrera-Chimal","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","article-title":"Nonsteroidal antagonists of the mineralocorticoid receptor","volume":"24","author":"Kolkhof","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"2023033113281082900_","first-page":"1801","article-title":"Studies on organ- and subcellular distribution of 3 H-spironolactone in animals","volume":"22","author":"Platt","year":"1972","journal-title":"Arzneimittelforschung"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1124\/mol.51.2.285","article-title":"Cell-specific, promoter-dependent mineralocorticoid agonist activity of spironolactone","volume":"51","author":"Massaad","year":"1997","journal-title":"Mol Pharmacol"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2003.10.008","article-title":"The 45-year story of the development of an anti-aldosterone more specific than spironolactone","volume":"217","author":"M\u00e9nard","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/1873-3468.13746","article-title":"Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150)","volume":"594","author":"Takahashi","year":"2020","journal-title":"FEBS Lett"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","article-title":"Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"43","author":"Pandey","year":"2022","journal-title":"Eur Heart J"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.21037\/apm-21-763","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis","volume":"10","author":"Fu","year":"2021","journal-title":"Ann Palliat Med"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.cardfail.2022.01.012","article-title":"Rates of spironolactone initiation and subsequent hyperkalemia hospitalizations in patients with heart failure with preserved ejection fraction following the TOPCAT trial: a cohort study of Medicare beneficiaries","volume":"28","author":"Desai","year":"2022","journal-title":"J Card Fail"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.2215\/CJN.02150221","article-title":"The RALES legacy and finerenone use on CKD patients","volume":"16","author":"Moura-Neto","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1053\/j.ajkd.2021.07.006","article-title":"Finerenone: fiddling with hyperkalemia?","volume":"78","author":"Waitzman","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease","volume":"79","author":"Bertocchio","year":"2011","journal-title":"Kidney Int"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1159\/000355736","article-title":"Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress","volume":"37","author":"Chen","year":"2013","journal-title":"Kidney Blood Press Res"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1159\/000518254","article-title":"Direct blood pressure-independent anti-fibrotic effects by the selective nonsteroidal mineralocorticoid receptor antagonist finerenone in progressive models of kidney fibrosis","volume":"52","author":"Droebner","year":"2021","journal-title":"Am J Nephrol"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41440-018-0187-1","article-title":"Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats","volume":"42","author":"Li","year":"2019","journal-title":"Hypertens Res"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.2147\/DDDT.S100095","article-title":"Spirolactone provides protection from renal fibrosis by inhibiting the endothelial-mesenchymal transition in isoprenaline-induced heart failure in rats","volume":"10","author":"Zhou","year":"2016","journal-title":"Drug Des Dev Ther"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/jcp.22783","article-title":"PAI-1 in tissue fibrosis","volume":"227","author":"Ghosh","year":"2012","journal-title":"J Cell Physiol"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling","volume":"93","author":"Barrera-Chimal","year":"2018","journal-title":"Kidney Int"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/ndt\/gfm694","article-title":"Macrophages contribute to the development of renal fibrosis following ischaemia\/reperfusion-induced acute kidney injury","volume":"23","author":"Ko","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.kint.2016.09.037","article-title":"Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality","volume":"91","author":"Carrero","year":"2017","journal-title":"Kidney Int"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress","volume":"9","author":"Gonz\u00e1lez-Bl\u00e1zquez","year":"2018","journal-title":"Front Pharmacol"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000521908","article-title":"Meta-analysis of the efficacy and safety of finerenone in diabetic kidney disease","volume":"47","author":"Zheng","year":"2022","journal-title":"Kidney Blood Press Res"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease","volume":"80","author":"Sato","year":"2016","journal-title":"Circ J"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41371-019-0207-x","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study","volume":"33","author":"Ito","year":"2019","journal-title":"J Hum Hypertens"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am J Nephrol"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ekir.2021.12.013","article-title":"The kidney protective effects of the sodium-glucose cotransporter-2 inhibitor, dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists","volume":"7","author":"Provenzano","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced","volume":"77","author":"Ferreira","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 2","key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"ehaa946.0939","DOI":"10.1093\/ehjci\/ehaa946.0939","article-title":"Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF","volume":"41","author":"Kristensen","year":"2020","journal-title":"Eur Heart J"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized cross-over clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2023033113281082900_","article-title":"A trial to learn how well finerenone works and how safe it is in adult participants with non-diabetic chronic kidney disease (FIND-CKD)"},{"key":"2023033113281082900_","article-title":"Study to evaluate the efficacy (effect on disease) and safety of finerenone on morbidity (events indicating disease worsening) & mortality (death rate) in participants with heart failure and left ventricular ejection fraction (proportion of blood expelled per heart stroke) greater or equal to 40% (FINEARTS-HF)"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"2023033113281082900_","article-title":"Efficacy and safety of KBP-5074 in uncontrolled hypertension and moderate or severe CKD (Clarion-CKD)"},{"key":"2023033113281082900_","article-title":"Spironolactone in the treatment of heart failure (SPIRIT-HF)"},{"key":"2023033113281082900_","article-title":"Spironolactone initiation registry randomized interventional trial in heart failure with preserved ejection fraction (SPIRRIT)"},{"key":"2023033113281082900_","article-title":"Aldosterone antagonist chronic hemodialysis interventional survival trial (ALCHEMIST)"},{"key":"2023033113281082900_","article-title":"Aldosterone blockade for health improvement evaluation in end-stage renal disease (ACHIEVE)"},{"key":"2023033113281082900_","article-title":"A study to learn more about how well the study treatment finerenone works, how safe it is, how it moves into, through, and out of the body, and the effects it has on the body when taken with an ACE inhibitor or angiotensin receptor blocker in children with chronic kidney disease and proteinuria (FIONA)"},{"key":"2023033113281082900_","article-title":"Efficacy, safety and tolerability of AZD9977 and dapagliflozin in participants with heart failure and chronic kidney disease (MIRACLE)"},{"key":"2023033113281082900_","article-title":"A study to learn how well the treatment combination of finerenone and empagliflozin works and how safe it is compared to each treatment alone in adult participants with long-term kidney disease (chronic kidney disease) and type 2 diabetes (CONFIDENCE)"},{"key":"2023033113281082900_","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","article-title":"Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy","volume":"67","author":"Grune","year":"2026","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfac322\/49333163\/gfac322.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/4\/845\/49715394\/gfac322.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/4\/845\/49715394\/gfac322.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T07:30:12Z","timestamp":1701502212000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/38\/4\/845\/6874761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":68,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12,6]]},"published-print":{"date-parts":[[2023,3,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfac322","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4]]},"published":{"date-parts":[[2022,12,6]]}}}